Abstract
Background: Ofloxacin (OFLX) is a fluoroquinolone-antibiotic with a broad antimicrobial spectrum that may have a potential role in the treatment of bacterial endophthalmitis. However, its elimination half life after intravitreal injection is short. To prolong the intravitreal antibacterial level OFLX was incorporated into liposomes. This study was performed to investigate the retinal toxicity of liposome-incorporated and free OFLX. Materials and methods: OFLX was incorporated into multilamellar large vesicles. 0,1 ml of this suspension (= 180.2 μg OFLX) was injected into the midvitreous of rabbit eyes (n = 6). Free OFLX in doses of 100 μg, 500 μg and 1,000 μg was injected into the midvitreous of a second group of rabbit eyes (n = 18). The other eye served as a control and received empty liposomes or normal saline solution, respectively. Before injection and at the end of follow-up an ERG was obtained. After a follow-up of 1 day, 14 and 28 days the animals were perfused with glutaraldehyde and the eyes were examined by light- and transmission electron microscopy. Results: The ERG as well as the histologic studies did not reveal any pathological changes after injection of liposome-incorporated OFLX compared to the control eyes. Significant reduction of the ERG was observed after 500 μg free OFLX in 2 out of 6 eyes after 1 and 14 days, respectively, and in 2 eyes 1 day after 1,000 μg free OFLX. Three days after injection of 1,000 μg OFLX the retina showed focal destruction in 1 out of 6 eyes. In another eye with the same dose 14 days after injection the photoreceptor outer segments showed disorganisation. Conclusion: This study shows that liposome-incorporated OFLX did not have any retinal toxicity in this animal model. Free OFLX appears to have no retinal toxicity in rabbit eyes at a dose of 100 μg after intravitreal injection. Injection of higher doses resulted in ERG changes and marked retinal damage.
Similar content being viewed by others
References
Chan PY, Leung YK, Ng, WWS. Comparative in vitro antibacterial activity of ofloxacin and ciprofloxacin against some selected gram-positive and gram-negative isolates. Infection 1986; 14(suppl. 4): 237–239.
Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol 1991; 112(suppl. 4): 15–24.
Sato K, Inoue Y, Fujii T, Aoyama H, Mitsuhashi S. Antibacterial activity of ofloxacin and its mode of action. Infection 1986; 14: 226–230
Behrens-Baumann W. Chinolone in der Augenheilkunde – Eine Literaturübersicht. Fortschr antimikrob antineoplast Chemother 1991; 10: 363–368.
Campochiaro PA, Lim JI, the Aminoglycoside Study Group. Aminoglycoside toxicity in the treatment of endophthalmitis. Arch Ophthalmol 1994; 112: 48–53.
Rosenbaum JD, Krumholz DM, Metz DM. Gentamicin retinal toxicity after cataract surgery in an eye that underwent vitrectomy. Ophthalm Surg Las 1997; 28: 236–238
Serdarevic ON. Role of fluoroquinolones in ophthalmology. Int Ophthalmol Clin 1993; 33: 162–178.
Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. Dissemination in japanese hospitals of strains of staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670–1673.
Kim SH, Kim JH, Cho KS, Kwak JS. Savety of intravitreally injected ciprofloxacin. Korean J Ophthalmol 1995; 9: 12–18.
Mochizuki K, Torisaki M, Kawasaki K, Shirao Y, Yamashita Y, Kitano K, Yonemura D. Retinal toxicity of antibiotics: evaluation by electroretinogram. Doc Ophthalmol 1988; 69: 195–202.
Rootman DS, Savage P, Hasany SM, Chisholm L, Basu PK. The toxicity and pharmacokinetics of intravitreal ciprofloxacin in rabbit eyes. Can J Ophthalmol 1992; 27: 277–282.
Wiechens B, Duncker G, Johannsen U, Burkhart M. Retinal toxicity of intravitreal ciprofloxacin in rabbit eyes. Invest Ophthalmol Vis Sci 1993; 34(4): 1425.
Wiechens B, Schütze D, Grammer J, Hedderich J, Pleyer U, Duncker G. Retinal toxicity of free and liposome-incorporated norfloxacin after intravitreal injection in rabbit eyes. Invest Ophthalmol Vis Sci 1997; 34(4): 1107.
Wiechens B, Neumann D, Grammer J, Pleyer U, Duncker G. Retinotoxizität von Ofloxacin in freier und liposomeninkorporierter Form in Kaninchenaugen. Ophthalmologe 1997; 94(Suppl. 1): 130.
Wiechens B, Neumann D, Krausse R, Grammer J, Pleyer U, Duncker G. Clearance von Ofloxacin in reiner und liposomeninkorporierter Form nach intravitrealer Injektion. Ophthalmologe 1996; 93(1 Suppl.): 53.
Coune A. Lipsomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience. Infection 1988; 16: 141–147.
Zeng S, Hu C, Wie H, Lu Y, Zhang Y, Yang J, Yun G, Zou W, Song B. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology 1993; 100: 1640–1644.
Alghadyan AA, Peyman GA, Khoobehi B, Liu K-R. Liposome-bound cyclosporine: Retinal toxicity after intravitreal injection. Int Ophthalmol 1988; 12: 105–107.
Fishman PH, Peyman GA, Cesar T. Intravitreal liposomeencapsulated gentamicin in a rabbit model. Invest Ophthalmol Vis Sci 1986; 27: 1103–1106.
Grammer JB. Topische Applikation von Liposomen als Medikamententräger in der Ophthalmologie: In-vitro- und In-vivo-Untersuchungen zum Einfluß physiko-chemischer Eigenschaften der Liposomen auf die okuläre Pharmakokinetik [Dissertation]. Fakultät für Biologie, Eberhard-Karls-Universität Tübingen, 1997.
Barza M, Baum J, Tremblay C, Szoka F, D'Amico DJ. Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. Am J Ophthalmol 1985; 100: 259–263.
Fishman PH, Peyman GA, Hendricks R, Hui SL. Liposome-encapsulated 3H-5FU in rabbits. Int Ophthalmol 1983; 13: 361–365.
Liu K-R, Peyman GA, Khoobehi B, Alkan H, Fiscella R. Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model. Ophthalmology 1987; 94: 1155–1159.
Liu K-R, Peyman GA, She SCH, Niesman, MR, Khoobehi B. Intravitreally injected liposome-encapsulated cytarabine. Ophthalmic Surg 1989; 20: 358–360.
New RCC. Liposomes. A practical approach. IRL Press, Oxford University Press, Oxford 1994; pp 33–104.
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research (1996); Institute of Laboratory Animal Resources (ILAR), Commission on Life Sciences, National Research Council, National Academy Press, Washington DC 1996.
Heine U. Beitrag zur Anästhesie von Kaninchen. Klin Monatsbl Augenheilkd 1982; 181: 195–196.
Bredehorn T. Ein neues Meßsystem für elektroretinographische Potentiale im tierexperimentellen Versuch [Disserta tion]. Medizinische Fakultät, Christian-Albrechts-Universität zu Kiel 1993.
Schmiederer M. Vergleichende elektroretinographische und morphologische Untersuchung der Rattenretina nach oraler Gabe des lipidoseinduzierenden Pharamakons Chloroquin [Dissertation]. Medizinische Fakultät, Christian-Albrechts-Universität zu Kiel 1993.
Dixon WJ, Brown MB, Engelman L, Jennrich RI. BMDP Statistical software manual. Vol. 1 and 2. University of California Press 1990.
McNeill D. Interactive Data Analysis. John Wiley, New York 1977; pp 1ff.
Maschmeyer G, Haralambie E, Gaus W, Kern W, Dekker AW, De Vries-Hospers HG, Sizoo W, König W, Gutzler F, Daenen S. Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia. Infection 1988; 16: 98.
Vogt P, Schorn T, Frei U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipients. Infection 1988; 16: 175.
Cokingtin CD, Hyndiuk RA. Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. Am J Ophthalmol 1991; 112: 25–28.
Cutarelli PE, Lass JH, Lazarus HM, Putman SC, Jacobs MR. Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. Curr Eye Res 1991; 10: 557–563.
Kaufman AH, Darrell RW, Shieh E, Landzberg B, Fay AM, Chin NX. Treatment of methicillin-resistant staphylococcus aureus keratitis in rabbits with ciprofloxacin, norfloxacin, ofloxacin, vancomycin and cefazolin. Invest Ophthalmol Vis Sci 1991; 32: 1171.
Loscos A, Ramos C, Barrientos S, Cabronero MJ, Zato M, Picazo JJ. Activity of ofloxacin in experimental keratitis. J Chemother 1991; 3(Suppl 4): 186–187.
Ogawa GSH, Hyndiuk RA. The fluoroquinolones: New antibiotics in ophthalmology. Int Ophthalmol Clin 1993; 33: 59–68.
Osato MS, Jensen HG, Trousdale MD, Bosso JA. The comparative in vitro activity of ofloxacin and selected ophthalmic antimicrobial agents against ocular bacterial isolates. Am J Ophthalmol 1989; 108: 380–386.
Rubinstein E, Mark Z, Keren G, Alkan M, Berger S, Bogokowski B. Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. Infection 1986;14: 20–25.
Behrens-Baumann W, Martell J. Ciprofloxacin concentration in the rabbit aqueous humor and vitreous body following intravenous and subconjunctival administration. Infection 1988; 16: 62–65.
Bron A, Talon D, Estavoyer JM, Cellier T, Delbosc B, Montard M. Ocular distribution of the new quinolones. Rev Infect Dis 1989; 11(suppl 5): 1206–1207.
Cohen RG, Raizman M, Callina C, Lahav M. Retinal safety of oral and topical ofloxacin in rabbits. J Ocul Pharmacol Ther 1997; 13: 369–379.
Denis F, Mounier M, Chauvin M, Adenis JP. Intraocular diffusion of ofloxacin into man and rabbit. 4. Int Symp on New Quinolones, Munich 1992; Abstracts, p 183.
Donnenfeld ED, Perry HD, Snyder R, Moadel K, Elsky M, Jones H. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol 1997; 115: 173–176.
Fukuda M, Sasaki K. Penetration of topically administered ofloxacin into ocular tissue. Folia Ophthalmol Jpn 1986; 37: 823–828.
Giamarellou H, Kanellas D, Kavouklis E, Petrikkos G, Gabriel L. Comparative pharmacokinetics of ciprofloxacin, ofloxacin and pefloxacin in human aqueous humour. Eur J Clin Mirobiol Infect Dis 1993; 12: 293–297.
O'Brien TP, Osterhout G, Dick JD. Comparative ocular penetration of topical ofloxacin and ciprofloxacin in rabbits. Invest Ophthalmol Vis Sci 1993; 34: 859.
Oomomo A. Intravitreal injection of norfloxacin and ofloxacin. I. Ocular pharmacokinetics. Atarashii Ganka 1991; 8: 291–295.
Perkins RJ, Drusano G, Madu A, Mayers M, Madu C, Miller MH. Pharmacokinetics of ofloxacin in serum and vitreous humor of albino and pigmented rabbits. Antimicrob Agents Chemother 1995; 39: 1493–1498.
Petrikkos G, Kanellas D, Giamarellou H, Kavouklis E, Chryssoulis Z, Gabriel L. Comparative humor kinetics of ciprofloxacin, ofloxacin and pefloxacin into the human eye. Eur J Clin Microbiol Infect Dis 1991; 10: 39–40.
Verbraeken H, Verstraete A, van de Velde E, Verschraegen G. Penetration of gentamicin and ofloxacin in human vitreous after systemic administration. Graefe's Arch Clin Exp Ophthalmol 1996; 234: 59–65.
Peyman GA. Antibiotic administration in the treatment of bacterial endophthalmitis. II. Intravitreal injections. Surv Ophthalmol 1977; 21: 332–346.
Mochizuki K, Torisaki M, Yamashita Y, Shirao Y, Sasaki T. Effects of vancomycin and ofloxacin on rabbit ERG in vivo. Nippon Ganka Gakkai Zasshi (Acta Soc Ophthalmol Jpn) 1989; 93: 322–328.
Mochizuki K, Torisaki M, Wakabayashi K. Effects of vancomycin and ofloxacin on rabbit ERG in vivo. Jpn J Ophthalmol 1991; 35: 435–445.
Mochizuki K., Higashide T, Torisaki M, Yamashita Y, Komatsu M, Ohkubo S, Ogata M, Ohnishi Y. Effects of nor-floxacin on the retina in rabbits. Graefe's Arch Clin Exp Ophthalmol 1995; 233: 173–180.
Kawasaki K, Mochizuki K, Torisaki M, Yamashita Y, Shirao Y, Wahabayashi K, Tanabe J. Electroretinographical changes due to antimicrobials. Lens Eye Tox Res 1990; 7: 693–704.
Kawasaki K, Ohnogi J. Nontoxic concentration of antibiotics for intravitreal use – evaluated by human in-vitro ERG. Doc Ophthalmol 1989; 70: 309–321.
Sakai H, Ochizuki K, Torisaki M, Yamashita Y, Komatsu M, Tanahashi T. Nontoxic intravitreal dose of ofloxacin for rabbit retina. Ophthalmic Res 1994; 26: 344–351.
Fukuda M, Sasaki K. Intraocular dynamic mode differences of new quinolone antibacterial agents between pigmented and albino rabbit eyes. Lens Eye Toxicity Res 1989; 6: 339–351.
Fukuda M, Sasaki K. Intraocular penetration of norfloxacin into the pigmented rabbit eye. Atarashii Ganka 1993; 10: 431–434.
D'Amico DJ, Caspers-Velu L, Libert J, Shanks E, Sdrooyen M, Hanninen LA, Kenyon KR. Comparative toxicity of intravitreal aminiglycoside antibiotics. Am J Ophthalmol 1985; 100: 264–275.
D'Amico DJ, Libert J, Kenyon KR, Hanninen LA, Caspers-Velu L. Retinal toxicity of intravitreal gentamicin. Invest Ophthalmol Vis Sci 1984; 25: 564–572.
Zemel A, Loewenstein A, Lei B, Lazar M, Perlman I. Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity. Invest Ophthalmol Vis Sci 1995; 36: 1875–1884.
Kaplan HJ, Cytryn AS, Parks DJ, Katz HR. Vitreous levels of ciprofloxacin after intravitreal injection in the rabbit. Invest Ophthalmol Vis Sci 1992; 33: 729.
Pearson PA, Hainsworth DP, Ashton P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina 1993; 13: 326–330.
Sawada, Y, Hatayama I, Sone K. Release of ofloxacin from silicone gel sheet. Br J Plast Surg 1993; 46: 576–579.
Giordano GG, Refogio MF, Arroyo MH. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invert Ophthalmol Vis Sci 1993; 42: 2743–2751.
Kimura H, Yuichiro O, Hashizoe M, Nishiwaki H, Honda Y, Ihada Y. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci 1994; 35: 2815–2819.
Peymann GA, Khoobehi B, Tawakol M, Schulman JA, Mortada HA, Alkan H, Fiscella R. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina 1989; 9: 232–236.
Pleyer U, Lutz S, Jusko WJ, Nguyen K, Narawane M, Rückert D, Mondino BJ, Lee VHL. Ocular absorption of topically applied FK506 from liposomal and oil formations in the rabbit eye. Invest Ophthalmol Vis Sci 1993; 34: 2737–2742.
Rao VS, Peyman GA, Khoobehi B, Vangipuram S. Evaluation of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis. Int Ophthalmol 1989; 13: 181–185.
Fresta M, Spadaro A, Cerniglia G, Ropero IM, Puglisi G, Furneri PM. Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts. Antimicrob Agents Chemother 1995; 39: 1372–1375.
Margolis LB. Introduction: Cell interaction with liposomes in liquid-crystalline and gel-phase state. In: Pleyer, U., Schmidt, K., Thiel, H.-J. (eds.): Liposomes in ophthalmology and dermatology. Hippokrates, Stuttgart 1993; pp 13–18.
Oh, Y-K, Nix DE, Straubinger RM. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Myobacterium avium infection. Antimicrob Agents Chemother 1995; 39: 2104–2111.
Onyegji CO, Nightingale CH, Nicolau DP, Quintiliani R. Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Myo-bacterium avium-M. intracellulare complex in human macrophages. Antimicrob Agents Chemother 1994; 38: 523–527.
Joondeph BC, Peyman GA, Khoobehi B, Yue BY. Liposome-encapsulated 5-Fluorouracil in the treatment of vitreoretinopathy. Ophthal Surg 1988; 19: 252–256.
Tremblay C, Barza M, Szika F, Lahav M, Baum J. Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits. Invest Ophthalmol Vis Sci 1985; 26: 711–718.
Peyman GA, Charles HC, Liu R, Khoobehi B, Niesman M. Intravitreal liposome-encapsulated drugs: A preliminary human report. Int Ophthalmol 1988; 12: 175–182.
Rights and permissions
About this article
Cite this article
Wiechens, B., Neumann, D., Grammer, J.B. et al. Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes. Int Ophthalmol 22, 133–143 (1998). https://doi.org/10.1023/A:1006137100444
Issue Date:
DOI: https://doi.org/10.1023/A:1006137100444